Astrocytes and brain-derived neurotrophic factor (BDNF)

Albini, Martina; Krawczun-Rygmaczewska, Alicja; Cesca, Fabrizia

doi:10.1016/j.neures.2023.02.001

Cited by 22 publications

(7 citation statements)

References 169 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, A2 astroglia partake in a neuroprotective sequence, releasing BDNF, which counteracts RAGE, and vascular endothelial growth factor (VEGF). VEGF not only promotes angiogenesis but also improves glucose transport to the brain and stimulates antioxidants, thereby contributing to neuroprotection [ 74 ].…”

Section: Pathophysiological Mechanisms Of Vcimentioning

confidence: 99%

Potential Intersections between lncRNA, Vascular Cognitive Impairment, and Immunization Strategies: Insights and Future Directions

Fan,

Xiao,

Zhang

2024

Vaccines

View full text Add to dashboard Cite

Vascular cognitive impairment (VCI) encompasses a wide range of cognitive disorders stemming from cerebrovascular issues, such as strokes or small vessel disease. These conditions often pose challenges to traditional diagnostic approaches due to their multifactorial nature and varied clinical presentations. Recently, next-generation sequencing (NGS) technologies have provided detailed analyses of long non-coding RNAs (lncRNAs) in the molecular pathobiology of VCI. These new findings help with molecular-based diagnostics and treatments of VCI. Within this realm, the concept of immune modulation, especially through specific vaccinations, emerges as a promising therapeutic strategy in VCI mitigation. In this review, we comprehensively elucidate the function of lncRNAs in VCI, emphasizing the advanced understanding of VCI’s molecular underpinnings made possible through NGS technologies. Significant focus is placed on the immune system’s role in VCI, particularly the neuroinflammatory processes which are consequential to cerebrovascular abnormalities. We believe that lncRNAs participate in regulating these immunological pathways, potentially guiding the development of vaccines targeting VCI. In this context, we propose a novel perspective: using knowledge about lncRNA profiles and functions to guide vaccine development, we can potentially exploit the body’s immune response to mitigate or prevent VCI. This approach has the potential to revolutionize VCI management by introducing targeted immunization strategies informed by molecular signatures, a concept that remains largely unexplored in current research endeavors. In addition, we summarize current progress and propose future directions, advocating for robust, interdisciplinary studies to validate the potential intersections between lncRNA landscapes, VCI pathology, and immunology. This review aims to spur innovative research and promote the development of lncRNA-informed vaccine strategies as proactive interventions against the cognitive consequences of VCI.

show abstract

Section: Pathophysiological Mechanisms Of Vcimentioning

confidence: 99%

Potential Intersections between lncRNA, Vascular Cognitive Impairment, and Immunization Strategies: Insights and Future Directions

Fan,

Xiao,

Zhang

2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…Astrocytes' close interplay with the endothelial cells ensures the barrier qualities by sustaining the existence of pumps and specialized ion channels, structures that are essential in maintaining transendothelial electrical resistance [27]. On the other hand, endothelin produced by the endothelial cells modulated astrocyte growth and differentiation by stimulating the production of nerve growth factors such as brain-derived neurotrophic factor (BDNF) [28]. Considering the functional anatomy of the spinal cord, the close interplay between neurons and astrocytes might also impact the astrocyte phenotype, with slight differences among the astrocytes located in the anterior and posterior horns and columns.…”

Section: The Blood-spinal Cord Barrier In Physiologic and Traumatic C...mentioning

confidence: 99%

Spinal Cord Injury Management Based on Microglia-Targeting Therapies

Schreiner,

Ciobanu

2024

JCM

View full text Add to dashboard Cite

Spinal cord injury is a complicated medical condition both from the clinician’s point of view in terms of management and from the patient’s perspective in terms of unsatisfactory recovery. Depending on the severity, this disorder can be devastating despite the rapid and appropriate use of modern imaging techniques and convenient surgical spinal cord decompression and stabilization. In this context, there is a mandatory need for novel adjunctive therapeutic approaches to classical treatments to improve rehabilitation chances and clinical outcomes. This review offers a new and original perspective on therapies targeting the microglia, one of the most relevant immune cells implicated in spinal cord disorders. The first part of the manuscript reviews the anatomical and pathophysiological importance of the blood-spinal cord barrier components, including the role of microglia in post-acute neuroinflammation. Subsequently, the authors present the emerging therapies based on microglia modulation, such as cytokines modulators, stem cell, microRNA, and nanoparticle-based treatments that could positively impact spinal cord injury management. Finally, future perspectives and challenges are also highlighted based on the ongoing clinical trials related to medications targeting microglia.

show abstract

“…Among the major compounds released by astrocytes during CNS development, two crucial factors that promote neurogenesis can be distinguished: gliogenesis and conferring trophic support; these factors correspond to brain-derived neurotrophic factor (BDNF) and insulin-like growth factor 1 (IGF-1) [51][52][53]. Locally secreted by glial cells, IGF-1 is one of the major factors regulating the differentiation of oligodendrocytes into mature cells and supporting the branching of their processes, which are capable of axon myelination [54].…”

Section: Astrocytes In Neurodevelopmentmentioning

confidence: 99%

Reactive Gliosis in Neonatal Disorders: Friend or Foe for Neuroregeneration?

Gargas,

Janowska,

Gebala

et al. 2024

Cells

View full text Add to dashboard Cite

A developing nervous system is particularly vulnerable to the influence of pathophysiological clues and injuries in the perinatal period. Astrocytes are among the first cells that react to insults against the nervous tissue, the presence of pathogens, misbalance of local tissue homeostasis, and a lack of oxygen and trophic support. Under this background, it remains uncertain if induced astrocyte activation, recognized as astrogliosis, is a friend or foe for progressing neonatal neurodevelopment. Likewise, the state of astrocyte reactivity is considered one of the key factors discriminating between either the initiation of endogenous reparative mechanisms compensating for aberrations in the structures and functions of nervous tissue or the triggering of neurodegeneration. The responses of activated cells are modulated by neighboring neural cells, which exhibit broad immunomodulatory and pro-regenerative properties by secreting a plethora of active compounds (including interleukins and chemokines, neurotrophins, reactive oxygen species, nitric oxide synthase and complement components), which are engaged in cell crosstalk in a paracrine manner. As the developing nervous system is extremely sensitive to the influence of signaling molecules, even subtle changes in the composition or concentration of the cellular secretome can have significant effects on the developing neonatal brain. Thus, modulating the activity of other types of cells and their interactions with overreactive astrocytes might be a promising strategy for controlling neonatal astrogliosis.

show abstract

Astrocytes and brain-derived neurotrophic factor (BDNF)

Cited by 22 publications

References 169 publications

Potential Intersections between lncRNA, Vascular Cognitive Impairment, and Immunization Strategies: Insights and Future Directions

Potential Intersections between lncRNA, Vascular Cognitive Impairment, and Immunization Strategies: Insights and Future Directions

Spinal Cord Injury Management Based on Microglia-Targeting Therapies

Reactive Gliosis in Neonatal Disorders: Friend or Foe for Neuroregeneration?

Contact Info

Product

Resources

About